X
[{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"DecentraNet","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for LL-37
Filters
Companies By Therapeutic Area
Details:
The most important finding from that clinical trial was that ropocamptide (LL-37) shows a significant effect in the patient subgroup with large wounds (≥10 cm2).
Lead Product(s):
Ropocamptide
Therapeutic Area: Podiatry
Product Name: LL-37
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 10, 2022
Details:
The funding will enable Maxwell to accelerate the development of its innovative platform having LL-37, recruit and retain top talent, pursue clinical trials, and scale up manufacturing capabilities.
Lead Product(s):
Ropocamptide
Therapeutic Area: Infections and Infectious Diseases
Product Name: LL-37
Highest Development Status: Preclinical
Product Type: Peptide
Partner/Sponsor/Collaborator:
DecentraNet
Deal Size: $10.8 million
Upfront Cash: Undisclosed
Deal Type: Financing
March 10, 2022